OTC:CC - Ocumetics Announces Appointment of Medical Advisory Board
(TheNewswire)
Calgary, Alberta – TheNewswire - October 11, 2022 - Ocumetics Technology Corp.(“ Ocumetics ” or the “ Company ”) ( TSXV:OTC)(OTC:OTCFF) (FRA:2QBO) hosted its first Medical Advisory Board (MAB)meeting on September 29, 2022, prior to the Annual Meeting of theAmerican Academy of Ophthalmology in Chicago, IL. The MAB will bechaired by Ocumetics’ Chief Medical Officer, Doyle Stulting, MD,PhD, and supported by a group of world renown key external experts whoattended the meeting. “This was a significant event for Ocumetics togather together our potential investigators, as we prepare for theupcoming clinical trials,” said Dr. Mark Lee, CEO ofOcumetics.
The design of the Ocumetics bionic lens was revealedfor the first time to ophthalmologists outside of the Company. Adiscussion ensued of the potential of the lens for providing bothdistance and near vision and its ability to rapidly accommodate anddisaccommodate. MAB member, Dr. B. J. Dupps commented, “It was avery stimulating meeting.”
“The Medical Advisory Board provided a fascinatingand informative discussion of Ocumetics’ lens technologies, both nowand in the future,” said Ocumetics Chief Scientific Officer &Founder, Dr. Garth Webb. Another MAB member, Dr. Francis Price, Jr,noted “We are fortunate to live in a timewhere we have access to new technology allowing us to see and functionbetter. For most of human history, people just accepted they wouldgradually go blind as they grew older.“
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company thatspecializes in adaptive lens designs. Ocumetics is in thepreclinical study stage of a game-changing technology for theophthalmic industry. Ocumetics has developed an expandableintraocular lens that fits within the natural lens compartment of theeye potentially to eliminate the need for corrective lenses. It isdesigned to allow the eye’s natural muscle activity to shift focusfrom distance to near.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dr. Mark Lee
President and CEO
(604) 832-6052
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theclinical trial program outlined above and that it will be conducted asexpected. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results andfuture events to differ materially from those expressed or implied bysuch forward-looking statements. Such factors include but are notlimited to: operational matters, historical trends, current conditionsand expected future developments, access to financing as well as otherconsiderations that are believed to be appropriate in thecircumstances. There can be no assurance that such statements willprove to be accurate, as actual results and future events could differmaterially from those anticipated in such statements. Accordingly,readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required bylaw.
Copyright (c) 2022 TheNewswire - All rights reserved.